Floatz logo

Shr-A1921

Brain Metastasis

Fudan UniversityPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

102 Active assets in the Brain Metastasis cohort.

Asset / SponsorPhaseRating
TRASTUZUMAB
Iambic Therapeutics, Inc
Phase 4BB
Zorifertinib
Alpha Biopharma (Jiangsu) Co., Ltd.
Phase 2/3BB
Icotinib
Betta Pharmaceuticals Co., Ltd.
Phase 3BB
Trastuzumab Deruxtecan
Baptist Health South Florida
Phase 4BB
Capecitabine
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3BB

View all 50 →

Same molecule, other indications

Shr-A1921 is also rated in:

ovarian cancerDormant
CCC
Indicative ·
54 / 100
View asset →
breast neoplasmDormant
CCC
Indicative ·
53 / 100
View asset →
Hormone Receptor Positive TumorDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →